Chugai Pharmaceutical (OTCMKTS:CHGCY) Sets New 1-Year High – What’s Next?

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) shares reached a new 52-week high on Thursday . The stock traded as high as $30.37 and last traded at $28.88, with a volume of 366799 shares traded. The stock had previously closed at $23.91.

Chugai Pharmaceutical Stock Up 20.8 %

The stock has a market capitalization of $95.04 billion, a price-to-earnings ratio of 37.51 and a beta of 0.80. The stock’s 50-day simple moving average is $23.50 and its 200 day simple moving average is $22.76.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its earnings results on Thursday, January 30th. The company reported $0.18 EPS for the quarter. Chugai Pharmaceutical had a return on equity of 21.53% and a net margin of 33.07%. As a group, equities research analysts anticipate that Chugai Pharmaceutical Co., Ltd. will post 0.74 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.